Lakefront Biotherapeutics NV current report, Q3 FY2018

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) on September 12, 2018. The registrant is a foreign private issuer headquartered in Mechelen, Belgium, filing under Rule 13a-16 of the Securities Exchange Act of 1934. The filing serves to incorporate by reference a press release dated September 12, 2018, attached as Exhibit 99.1.

Key Financial Metrics

The provided filing text does not contain specific financial data. It acts as a cover document referencing an external press release. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this text.

Material Changes

The filing text does not detail specific material changes or comparative period data. It solely indicates the issuance of a press release on the filing date.

Guidance, Outlook, and Risks

Management commentary, guidance, outlook, risks, and contingencies are contained within the referenced press release (Exhibit 99.1), the text of which is not included in the provided input. The filing confirms the press release is incorporated into the Company's Registration Statements on Forms F-3 and S-8.

Investor Verification Checklist

  • Verify the actual content of the press release dated September 12, 2018 (Exhibit 99.1), as the filing text only references it.
  • Confirm the registrant name is Galapagos NV, noting a discrepancy with the metadata provided.
  • Review the referenced Registration Statements (Forms F-3 and S-8) for context on how this press release impacts outstanding securities.
  • Check for subsequent filings if the press release contained forward-looking statements requiring updates.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.